Bone and Cancer Working Group

Members

Chair: R Rizzoli     
Members: JJ Body,  ML Brandi, M Campusano, J Cannata-Andia, M Chakhtoura, D Chappard, C Confavreux, P Ebeling, G El Hajj Fuleihan, A El Maghraoui, C Glüer, G Guglielmi,  P Hadji, G Holzer, D Kendler, N Napoli, A Papaioannou, T de Villiers

Aim

To define and assess the effects on bones following a cancer or cancer treatment.

Projects

Cancer in children: Bone loss and its management in relation to cancer in children and adolescents and in response to chemotherapy, radiation and surgery.

Optimal duration of bone targeting agent (BTA) administration in patients with tumour bone disease: Questions to be answered: When to start? When to stop? When to decrease the treatment intensity? With a focus on bone metastasis and not myeloma.

New treatments in multiple myeloma: To review effects on bones of the new treatments in the management of multiple myeloma.

Publications

Bone management in hematologic stem cell transplant recipients.

Kendler, D., Body, J., Brandi, M. et al. for the International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer and Bone Disease.

Osteoporosis International (2018). DOI 10.1007/s00198-018-4669-4

https://link.springer.com/article/10.1007%2Fs00198-018-4669-4

The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation.

Cianferotti, L., Bertoldo, F., Carini, M. et al.

Oncotarget (2017). DOI 10.18632/oncotarget.17980

https://doi.org/10.18632/oncotarget.17980

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG.

Hadji, P., Aapro, M., Body, J. et al.

Journal of Bone Oncology (2017). DOI 10.1016/j.jbo.2017.03.001

https://www.sciencedirect.com/science/article/pii/S2212137417300258

Cancer-associated bone disease.

Rizzoli, R., Body, J., Brandi, M. et al. for the International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer-Induced Bone Disease.

Osteoporosis International (2013). DOI 10.1007/s00198-013-2530-3

http://link.springer.com/article/10.1007/s00198-013-2530-3